How to Get Rid of Blood Clots: What Actually Works

Blood clots are treated primarily with anticoagulant medications that stop a clot from growing and let the body’s own enzymes dissolve it over time, though in life-threatening situations doctors may use clot-busting drugs or physically pull the clot out. The right approach depends heavily on where the clot is, how dangerous it is, and how long it has been there. What surprises many people is that most treatments don’t “get rid of” a clot directly; they create the conditions for your body to break it down on its own, a process that can take weeks to months.

Different Clots Need Different Treatments

Before anything else, the type and location of a blood clot determines the entire treatment strategy. A clot in a superficial leg vein, while painful, is a fundamentally different problem from one lodged in a deep vein or blocking an artery in the brain. Superficial vein thrombosis was long considered minor and self-limiting, treated with little more than anti-inflammatory drugs and compression. That view has shifted somewhat: research shows superficial clots share the same risk factors as deep vein thrombosis and can extend into deeper veins or even lead to a pulmonary embolism. When a superficial clot sits within a few centimeters of the junction where the superficial vein meets the deep venous system, it is treated essentially the same as a DVT, with full anticoagulation.¹

Deep vein thrombosis and pulmonary embolism sit at the more serious end of the spectrum and almost always require anticoagulant therapy. Arterial clots, like those causing strokes or heart attacks, often demand emergency intervention within a narrow time window. Knowing which category your clot falls into is not just medical trivia; it directly determines whether you’ll be sent home with a prescription, admitted for an IV drip, or wheeled into a procedure room.

Anticoagulants: The Workhorse Treatment

For the vast majority of people diagnosed with DVT or pulmonary embolism, treatment means blood thinners. These drugs don’t literally dissolve a clot. Instead, they block the clotting cascade so the existing clot stops growing, and your body’s natural fibrinolytic system gradually breaks it down. Think of it like cutting off supply lines to a fire rather than hosing it down directly.

The newer direct oral anticoagulants, commonly called DOACs, have become the standard first choice for most patients. Drugs like rivaroxaban and apixaban are taken as pills, don’t require the frequent blood monitoring that older drugs like warfarin demand, and carry a somewhat lower risk of major bleeding. Warfarin is still used in specific situations, particularly for people with mechanical heart valves or certain clotting disorders, but for a typical DVT or PE it has largely been displaced.

Injectable heparins, including low-molecular-weight heparin, are used when a fast-acting anticoagulant is needed right away, such as in the hospital setting or as a bridge while oral drugs take effect. The duration of anticoagulant therapy varies. A first-time DVT triggered by a clear, temporary risk factor like surgery might need only three months of treatment. A clot with no identifiable trigger, or a second episode, often leads to indefinite therapy because the risk of recurrence remains elevated.

Clot-Busting Drugs for Emergencies

When a blood clot is immediately life-threatening, anticoagulants alone aren’t fast enough. That’s where thrombolytics, also called fibrinolytics, come in. These drugs actively dissolve the clot by converting plasminogen into plasmin, the enzyme that chews through the fibrin mesh holding the clot together. The most well-known is alteplase (tPA), though tenecteplase is increasingly used.

The catch is that thrombolytics work under strict conditions. For stroke patients, treatment is only an option if the person arrives within roughly three to four and a half hours of symptom onset, shows clear neurological deficits, and has no signs of bleeding in the brain. For massive pulmonary embolism with dangerously low blood pressure, fibrinolytics reduce the risk of dying. And for heart attacks, they are used when a cardiac catheterization lab isn’t available quickly enough.²

The trade-off is serious: the most significant complication is major bleeding, including bleeding in the brain. This risk is highest in stroke patients compared to those treated for heart attack or PE.² That’s why these drugs are reserved for situations where the clot poses an immediate threat to life or limb, not for a stable DVT in the leg.

Mechanical Thrombectomy: Physically Removing a Clot

Sometimes the fastest way to deal with a dangerous clot is to go in and pull it out. Mechanical thrombectomy has become a critical treatment for large-vessel strokes that don’t respond to or aren’t candidates for clot-busting drugs. A catheter is threaded through a blood vessel, usually starting from the groin, up to the site of the blockage, where the clot is either suctioned out or captured with a retrieval device.

The results can be striking. In one large real-world series using a modern aspiration technique for stroke, doctors achieved successful blood flow restoration in about 97% of cases regardless of which specific technique was used, and over half the procedures succeeded on the very first pass.³ These numbers are from a specialized center, and outcomes vary, but the procedure has become standard of care for eligible stroke patients.

Catheter-based procedures aren’t limited to the brain. For massive DVT or intermediate-risk PE, catheter-directed thrombolysis delivers clot-busting drugs directly to the clot site through a thin tube, using lower drug doses than a full systemic infusion and potentially reducing the bleeding risk. Some newer devices combine mechanical disruption of the clot with local drug delivery or suction. These approaches are evolving rapidly and are increasingly offered at major medical centers, though they aren’t appropriate for every patient.

IVC Filters: A Safety Net, Not a Cure

An inferior vena cava filter is a small, cage-like metal device placed inside the large vein that carries blood from your lower body back to your heart. Its job is to catch clots migrating from the legs before they reach the lungs and cause a PE. Filters don’t treat or dissolve existing clots; they’re a physical barrier.

Doctors typically place retrievable IVC filters in patients who have an acute clot but can’t safely take blood thinners, perhaps because of a recent surgery, active bleeding, or a high fall risk. The intention is usually to remove the filter once the patient can start anticoagulation. In practice, though, removal rates are disturbingly low. One study found that only about 30% of placed filters were actually retrieved.⁴

Filters left in place long-term can cause their own problems. Complications include the filter tilting, embedding into the vessel wall, clotting off the filter itself, and even perforating the vena cava.⁵ If you’ve had a filter placed, the most important follow-up step is making sure it gets removed once it’s no longer needed. If your doctor placed one during a hospitalization and nobody has mentioned taking it out, it’s worth bringing up.

Compression Stockings and Movement During Recovery

Once you’re diagnosed with a DVT and started on blood thinners, you might assume the prescription is bed rest. Older medical thinking supported that idea, reasoning that moving around could dislodge a clot and send it to the lungs. Research has largely overturned that concern. A systematic review found that early exercise in patients with acute DVT carried a similar short-term risk of pulmonary embolism compared with bed rest, and actually led to faster resolution of leg pain.⁶ Walking and staying mobile, as tolerated, is now the standard recommendation for most DVT patients on anticoagulation.

Compression stockings are a separate question, and the evidence there is more nuanced. The main purpose of wearing graduated compression stockings after a DVT isn’t to treat the clot itself but to prevent a long-term consequence called post-thrombotic syndrome, which involves chronic leg swelling, pain, and skin changes. Multiple randomized trials have shown a meaningful benefit: compression stocking use reduced the frequency and severity of PTS by roughly 16 to 27 percentage points in several studies, a finding supported by meta-analysis.⁷ Knee-length stockings work just as well as thigh-length ones, which is good news for comfort and compliance.

If you’re wondering whether a milder compression level would be easier to live with, a trial comparing lower-pressure and higher-pressure stockings found the lower-pressure version appeared no worse at preventing PTS.⁸ The practical takeaway: wearing the stockings consistently matters more than choosing the maximum pressure level.

Can Natural Remedies Dissolve Blood Clots?

This is where people tend to get into trouble. A quick internet search will surface claims about nattokinase, turmeric, bromelain, fish oil, and various supplements that supposedly thin the blood or dissolve clots. The most studied of these is nattokinase, an enzyme derived from fermented soybeans, and it does have genuinely interesting properties in the lab. It can break down fibrin directly and has been shown in animal studies to dissolve experimentally created clots.⁹

In healthy human volunteers, a single oral dose of nattokinase boosted markers of clot breakdown and mildly prolonged clotting time, though all measured values stayed within normal ranges.¹⁰ A Phase II clinical trial in the U.S. has looked at nattokinase for prevention of atherosclerosis-related clotting.¹¹

Here’s the critical distinction: showing that a supplement has measurable effects on blood markers in healthy volunteers is very different from showing it can treat an actual blood clot safely and effectively. No nattokinase study has demonstrated that it can replace anticoagulant therapy for a diagnosed DVT or PE. Taking nattokinase instead of a prescribed blood thinner is genuinely dangerous. The other risk runs in the opposite direction: taking nattokinase alongside blood thinners could amplify the anticoagulant effect and increase bleeding risk. If you’re interested in trying nattokinase for general cardiovascular health, that’s a conversation to have with a doctor who knows your full medication list. It is not a substitute for medical treatment of an existing clot.

How Clots Get Found in the First Place

Treatment can’t start without a diagnosis, and the diagnostic process for blood clots has become increasingly sophisticated. The classic approach to suspected DVT involves a clinical scoring system that estimates the probability based on symptoms and risk factors, followed by a D-dimer blood test. D-dimer measures a fragment produced when clots break down; a low level in a low-risk patient essentially rules out DVT without imaging. When D-dimer is elevated or clinical suspicion is higher, an ultrasound of the leg veins provides the definitive answer.

A refinement to this approach adjusts the D-dimer threshold based on clinical probability, which cuts down on unnecessary ultrasound scans. In a large prospective study, using probability-adjusted D-dimer thresholds safely ruled out DVT and reduced the need for ultrasound by about 47% compared with the traditional strategy, with only about 0.6% of patients who were cleared going on to develop a clot during follow-up.¹² For pulmonary embolism, CT angiography is the standard imaging test, giving a rapid, detailed picture of whether a clot is sitting in the lung arteries.

Why does this matter for “getting rid of” a clot? Because speed of diagnosis directly affects treatment options. A stroke patient who reaches the hospital within the treatment window has access to thrombolytics and thrombectomy. A PE patient diagnosed early enough can receive anticoagulation before the clot grows or fragments. A DVT caught before it propagates into larger veins is simpler to manage. The diagnostic step is inseparable from the treatment step.

Why Blood Clots Form and Who’s at Higher Risk

Understanding why clots form helps explain why “getting rid” of them sometimes means addressing the underlying cause, not just the clot itself. The classic trio of risk factors involves sluggish blood flow, damage to the blood vessel lining, and a blood that’s chemically primed to clot more easily than normal. Anything that hits one or more of these triggers raises the risk.

The most common situational triggers include major surgery, prolonged immobility (long flights, hospitalization), pregnancy, and hormonal contraception. Cancer is a particularly potent risk factor. Tumor cells can directly activate the clotting cascade and release substances that make the blood hypercoagulable.¹³ The relationship goes further: cancer cells interact directly with platelets, the vessel lining, and immune cells to ramp up clot formation, and some cancer treatments themselves add to the risk.¹⁴ This is why an unprovoked blood clot in someone with no obvious risk factors sometimes prompts doctors to screen for an underlying malignancy.

On the genetic side, inherited conditions like Factor V Leiden or prothrombin gene mutations make the blood clot more readily. More recently, researchers have found that even mutations affecting red blood cell structure can contribute: certain gain-of-function mutations that cause red cells to lose water and stiffen have been linked to increased risk of clotting events.¹⁵ The picture emerging from this work is that clotting risk isn’t just about the clotting proteins themselves; the physical properties of blood cells matter too.

Preventing Clots During Travel and Prolonged Sitting

One of the most common questions people have about blood clots is how to avoid them on long flights or during extended periods of sitting. The core issue is that sitting motionless for hours lets blood pool in the lower legs, slowing venous return and creating conditions ripe for clot formation. Research using simulated long-haul flights has quantified this: sitting still for six and a half hours dropped blood flow in the main thigh artery by a meaningful amount. Interestingly, a seat designed to passively shift the sitter’s posture and pressure distribution prevented that blood flow decline entirely.¹⁶

You don’t need a specialized seat to get a similar effect. The practical strategies are straightforward: get up and walk the aisle periodically, flex and extend your ankles while seated, stay hydrated, and avoid crossing your legs for long stretches. For people with additional risk factors, like a prior DVT, recent surgery, or an active cancer, a doctor might recommend wearing compression stockings during the flight or even taking a dose of anticoagulant before travel. These measures are genuinely effective, and they don’t require buying supplements or gadgets.

Treatments on the Horizon

The biggest limitation of all current anticoagulants is that they reduce clotting and increase bleeding. Every blood thinner works by interfering with the same basic clotting machinery your body uses to stop you from bleeding when you cut yourself. This creates a constant balancing act between preventing dangerous clots and causing dangerous bleeds.

A new class of drugs in development aims to break this compromise. These drugs target Factor XI, a protein involved in an arm of the clotting system that appears to drive pathological clot formation but plays a smaller role in normal wound-healing. The reasoning comes partly from observing that people born with low Factor XI levels have a lower rate of blood clots but don’t tend to bleed excessively.¹⁷ Several Factor XI inhibitors are now in clinical trials, using approaches that include small-molecule drugs, antibodies, and antisense oligonucleotides that reduce the liver’s production of the protein. Early-phase trials have been encouraging, but whether they deliver on the promise of effective clot prevention with substantially less bleeding remains to be seen in larger, longer studies.

Other research is exploring ways to enhance the body’s own clot-dissolving system, develop more targeted drug delivery methods that concentrate thrombolytics at the clot site while minimizing exposure to the rest of the body, and better identify which patients will benefit from aggressive treatment versus watchful waiting. The field is moving quickly, and the treatment landscape a decade from now will look quite different from today’s.

When a Clot Comes Back

Recurrence is one of the most frustrating aspects of venous thromboembolism. After a first DVT or PE, the risk of having another clot within ten years is substantial, particularly if the first episode was unprovoked. This is why the decision about how long to continue anticoagulation is so consequential and so individualized.

The calculus changes depending on context. A DVT that happened after knee surgery in an otherwise healthy 35-year-old has a low recurrence risk once the surgical trigger is gone, so three months of anticoagulation is usually enough. An unprovoked PE in a 60-year-old with obesity and a family history of clotting is a different story; that person may benefit from staying on a blood thinner indefinitely, accepting the ongoing bleeding risk as the lesser of two dangers. Factors that push toward longer treatment include male sex, elevated D-dimer after stopping treatment, residual clot on follow-up ultrasound, and the presence of a persistent risk factor like active cancer.

For people taken off anticoagulation, there are no proven strategies to eliminate recurrence risk entirely. Maintaining a healthy weight, staying physically active, avoiding prolonged immobility, and managing modifiable risk factors like smoking are sensible but don’t bring the risk to zero. Some patients end up making repeated treatment decisions over a lifetime, starting and stopping anticoagulation as their risk profile shifts. It’s a long game, and the conversations about treatment duration are among the most important ones you can have with your hematologist or vascular specialist.